A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases

Clinical Cancer Research

Volumn 7, Issue 3, 2001, Pages 478-485

  Berenson, James R ^a,b   Vescio, Robert A ^a,b   Rosen, Lee S ^a,b   Vonteichert, Joseph M ^a,b   Woo, Margie ^a,b   Swift, Regina ^a,b   Savage, Allison ^a,b   Givant, Elise ^c   Hupkes, Mieke ^c   Harvey, Harold ^c   Lipton, Allan ^c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BIOLOGICAL RESPONSE MODIFIER; BISPHOSPHONIC ACID DERIVATIVE; COLONY STIMULATING FACTOR; CORTICOSTEROID; CYTOKINE; CYTOTOXIC AGENT; HORMONE; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE METASTASIS; BONE PAIN; BONE RADIOGRAPHY; CANCER; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OSTEOLYSIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; UPPER RESPIRATORY TRACT INFECTION; URINALYSIS;

ADULT; AGED; BONE NEOPLASMS; BONE RESORPTION; CREATININE; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; TIME FACTORS;

EID: 0034906503     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
2. Multiple myeloma: A review of 869 cases
3. Bone destruction and hypercalcemia in plasma cell myeloma
4. Factors regulating the growth of metastatic cancer in bone
5. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development
6. Rationale for the use of bisphosphonates in bone metastases
7. Mechanisms of osteolytic bone destruction
8. Synergistic interactions between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption
9. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
10. Current use of bisphosphonates in oncology
11. Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate
12. Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: A randomized comparison between a 3-day treatment and single 24-hour infusions
13. Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcemia caused by cancer
14. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD)
15. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases
16. Inhibition of bone resorption by bisphosphonates: Interactions between bisphosphonates, osteoclasts, and bone
17. Bisphosphonates: Mechanisms of action and clinical use in osteoporosis - An update
18. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo
19. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia
20. Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma
21. Comparative study of available medical therapy for hypercalcemia of malignancy
22. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosages
23. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer
24. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcemia
25. Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate [APD]) as single shot treatment of hypercalcemia
26. Structure-activity relationships of various bisphosphonates
27. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the biphosphonate AHPrBP
28. A single-day treatment of tumor-induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonate
29. Palliative pamidronate treatment in patients with bone metastases from breast cancer
30. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs
31. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates
32. Bisphosphonates inhibit breast cancer cell proliferation
33. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
34. Overview of bisphosphonates
35. Bisphosphonates induce apoptosis in human myeloma cell lines: A novel antitumour activity
36. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound
37. Clinical research update: Zoledronate
38. Zoledronate (CGP 42'446) suppresses turnover without affecting mineralization in cancellous bone of the ovariectomized nonhuman primate
39. Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys
40. Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models
41. A dose-finding study of zoledronate in hypercalcemic cancer patients
42. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: A double-blind, randomized, dose-response study
43. A Phase I, open label, dose-ranging, trial of intravenous-bolus zoledronic acid, a novel bisphosphonate, in cancer patients with osteolytic bone lesions
44. Double-blind, randomized, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease
45. Markers of bone resorption in patients treated with pamidronate
46. Assessment of bone response to systemic therapy in an EORTC trial: Preliminary experience with the use of collagen cross-link excretion
47. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy
48. The palliation of symptomatic osseous metastases: Final results of the study by the Radiation Therapy Oncology Group
49. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate
50. J.f.t.P.1 A.B.C.S.G. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
51. Disposition and nephrotoxicity of 3 -amino-1-hydroxypropylidene-1, 1-bisphosphonate (APD), in rats and mice
52. The pharmacokinetics and distribution of pamidronate for a range of doses in the mouse
53. Bisphosphonates: A review of their pharmacokinetic properties
54. Immunoassay for quantifying type I collagen degradation products in urine evaluated
55. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine
56. Urinary pyridinium crosslinks of collagen: Specific markers of bone resorption in metabolic bone disease
57. Novel serum markers of bone resorption: Clinical assessment and comparison with established urinary indices
58. Biochemical markers of bone metabolism: An overview
59. Clinical utility of biochemical markers of bone remodeling
60. Bone markers in clinical practice
61. Relationships between biochemical and symptomatic response in a double-blind randomized trial of pamidronate for metastatic bone disease
62. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment
63. Molecular mechanisms of action of bisphosphonates